Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Intellego: Expert Advice for Choosing and Using UV-C Disinfection Systems for Your Facility

“Deploying UV-C technology requires meeting facility needs and ensuring they know how to use it and validate it that it’s working properly.” Disinfection is at the forefront of everyone’s mind in a pandemic. As a result, most facilities need a portfolio of tools to support this, with UV-C being one of those. But how can…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Intellego: Expert Advice for Choosing and Using UV-C Disinfection Systems for Your Facility

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

“Deploying UV-C technology requires meeting facility needs and ensuring they know how to use it and validate it that it’s working properly.”

Disinfection is at the forefront of everyone’s mind in a pandemic. As a result, most facilities need a portfolio of tools to support this, with UV-C being one of those. But how can organizations implement it and ensure it’s working? In this discussion, host Daniel Litwin spoke to two subject matter experts, Wendy Brady-Walling, Director of Global Marketing, Intellego Technologies, and Christine Gallo, CEO, Gallo Medical Company and IP Program.

Gallo, already in the medical industry, became a bigger advocate for infection prevention and disinfection after a family member’s health battle. “I realized we have to do better, and that’s what led me to add UV-C to the toolbox to help with this,” she said.

Gallo’s objective now is to partner with facilities to help them find funding to acquire and deploy UV-C disinfection systems and ensure it’s working by using UV-C dosimeters, which provide visual validation of disinfection. She noted that dosimeters are included in the purchase of the UV-C equipment and that her team trains staff on how to use them.

Brady-Walling discussed the many delivery systems of UV-C, from mobile towers to ceiling mounts to autonomous robots. “Pre-COVID, UV-C disinfection systems were considered ‘nice to have.’ Now they’re a ‘need to have.’ That’s why we’re focused on educating industries about its availability, safety, efficacy, and efficiency.”

The pandemic also meant using UV-C in new spaces, including restaurants, airports, gyms, and office buildings. In the healthcare setting, UV-C was in use in operating rooms. “They are using it in patient rooms prior to staff cleaning, so it’s safer for them. We just deployed it at a cancer center.”

Brady-Walling added, “They love the technology and the visual evidence from the dosimeter that it was a successful disinfection.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512